Veraxa Biotech signs USD 27.5 million senior secured note financing tied to Voyager Acquisition merger

• VERAXA Biotech agreed to issue a USD 27.5 million senior secured note, tied to its business combination with Voyager Acquisition Corp.
• Funding is expected to occur concurrently with the closing; the note has a 15-month term with monthly amortization starting three months post-close.
• The note is secured by all VERAXA assets; VERAXA may redeem at par without penalty, subject to conditions.
• VERAXA also signed a USD 50 million share purchase agreement with Lincoln Park Capital to sell stock over 24 months at market-based prices.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-26-005814), on May 29, 2026, and is solely responsible for the information contained therein.